Surgical Management after Doxorubicin and Epirubicin Extravasation
Authors:
- 1 October 1998
- journal article
- case report
- Published by SAGE Publications in Journal of Hand Surgery (European Volume)
- Vol. 23 (5) , 666-668
Abstract
Doxorubicin and epirubicin are strong antineoplastic agents widely used in chemotherapy. One major complication of their use is skin sloughing after subcutaneous extravasation, the degree of which is often underestimated. Both drugs have a tendency to produce liquefying necrosis in soft tissue and chronic ulcers if extravasation occurs. Three cases of extravasation, their surgical treatment and final results are presented. In cases of doxorubicin and epirubicin extravasation it is very important to perform an early extensive surgical débridement with delayed closure to avoid-long hospitalization and disabling results.Keywords
This publication has 8 references indexed in Scilit:
- Prevention and Management of Extravasation of Cytotoxic DrugsDrug Safety, 1995
- Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approachCancer Chemotherapy and Pharmacology, 1992
- Cytostatic extravasation. A serious complication of long-term venous accessCancer, 1991
- Cytostatic ExtravasationsAnnals of Plastic Surgery, 1987
- What Is the Appropriate Management of Tissue Extravasation by Antitumor Agents?Plastic and Reconstructive Surgery, 1985
- What Is the Appropriate Management of Tissue Extravasation by Antitumor Agents?Plastic and Reconstructive Surgery, 1985
- Toxic lesions of the hand associated with chemotherapyThe Journal of Hand Surgery, 1983
- Management of extensive doxorubicin hydrochloride extravasation injuriesThe Journal of Hand Surgery, 1983